AstraZeneca shares: 3 reasons to consider buying now

Jon Smith explains the reasons why he’s positive about AstraZeneca shares right now, despite the fall yesterday following results.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Yesterday, AstraZeneca (LSE:AZN) announced results for the third quarter. The results were a mixed bag, with AstraZeneca shares actually falling on Friday morning. Even with this, I think there are several reasons to be bullish about the stock and the company. Let me explain in more detail.

Socially responsible

The first reason I’m keen is due to the positive ESG impact. I’ve written a lot recently about how such investing is here to stay and is growing in demand. Therefore, picking stocks that have an appeal for ESG investors should see prolonged demand in the future.

AstraZeneca fit the bill (in my opinion) on this front. For one point, the company is not making a profit from the production and distribution of the Covid-19 vaccine so far and only plans to make a modest profit post-pandemic. In the latest results, sales from the previous quarter for the vaccine stood at a chunky $1.05bn. From a social point of view, this is a good move. Making profit from the vaccine during the pandemic would have been lucrative, but not the right thing to do.

The company also publishes a sustainability report each year, with a push towards making healthcare more accessible to people around the world. 

A strong track record

Another reason to buy AstraZeneca shares is the track record of performance. The share price over the past decade has been a pretty straight line moving higher. Over all of the timeframes I consider (three, six, 12 and 24 months), the share price would have given me a profitable return. Granted, it’s not always particularly high. For example, over a one-year period I’d have gained 7.5%. But the point here is that the stock has relatively low volatility and is in a strong long-term trend moving higher.

For a potential investor, this set-up is appealing. I want to have stocks like this in my portfolio that should hopefully provide me with steady returns. I can then look to take more risks on other stocks. When I bring everything together, my overall stock portfolio risk should still be balanced, thanks to the mix that I include.

Positive about AstraZeneca shares, but not without risks

Finally, I think the latest results were positive. Revenue for the quarter came in at $9.9bn, an increase of 48% versus the same period last year. This was driven in part thanks to the acquisition and integration of Alexion. 

Even with this, good percentage growth was seen across multiple segments from a year-to-date perspective. Product sales were up 29%, oncology division revenue was up 16% and CVRM revenue was up 10%. These drivers should allow the company to meet the full-year guidance provided earlier this year.

In terms of risks, the business noted that Covid-19 is still going to cause issues. When commenting on the virus impact, it said that “variations in performance between quarters can be expected to continue”.

I also think it needs to keep an eye on expenses. Total operating expenses increased year-to-date by 34% to over $17bn. 

Overall, I think the company is doing well and so am considering buying AstraZeneca shares right now.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jon Smith and The Motley Fool UK have no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Prediction: these FTSE 100 stocks could be among 2025’s big winners

Picking the coming year's FTSE 100 winners isn't an easy task, but we're all thinking about it at this time…

Read more »

Investing Articles

This UK dividend share is currently yielding 8.1%!

Our writer’s been looking at a FTSE 250 dividend share that -- due to its impressive 8%+ yield -- is…

Read more »

Investing Articles

If an investor put £10,000 in Aviva shares, how much income would they get?

Aviva shares have had a solid run, and the FTSE 100 insurer has paid investors bags of dividends too. How…

Read more »

Investing Articles

Here’s why I’m still holding out for a Rolls-Royce share price dip

The Rolls-Royce share price shows no sign of falling yet, but I'm still hoping it's one I can buy on…

Read more »

Investing Articles

Greggs shares became 23% cheaper this week! Is it time for me to take advantage?

On the day the baker released its latest trading update, the price of Greggs shares tanked 15.8%. But could this…

Read more »

Investing Articles

Down 33% in 2024 — can the UK’s 2 worst blue-chips smash the stock market this year?

Harvey Jones takes a look at the two worst-performing shares on the FTSE 100 over the last 12 months. Could…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

Are National Grid shares all they’re cracked up to be?

Investors seem to love National Grid shares but Harvey Jones wonders if they’re making a clear-headed assessment of the risks…

Read more »

Investing For Beginners

Here’s what the crazy moves in the bond market could mean for UK shares

Jon Smith explains what rising UK Government bond yields signify for investors and talks about what could happen for UK…

Read more »